The Aporia
The Aporia
Impulse Dynamics® Presented Real-World, Late-Breaking Data Revealing Heart Failure Hospitalization Reduction and Sustained Clinical Benefits of CCM® Therapy at One Year. (2026, October 12). Toronto Star. https://www.thestar.com/globenewswire/impulse-dynamics-presented-real-world-late-breaking-data-revealing-heart-failure-hospitalization-reduction-and-sustained/article_622f1936-fec0-5ee8-84ec-942ff4bcd12c.html
“Impulse Dynamics® Presented Real-World, Late-Breaking Data Revealing Heart Failure Hospitalization Reduction and Sustained Clinical Benefits of CCM® Therapy at One Year.” Toronto Star, 12 Oct. 2026, https://www.thestar.com/globenewswire/impulse-dynamics-presented-real-world-late-breaking-data-revealing-heart-failure-hospitalization-reduction-and-sustained/article_622f1936-fec0-5ee8-84ec-942ff4bcd12c.html.
“Impulse Dynamics® Presented Real-World, Late-Breaking Data Revealing Heart Failure Hospitalization Reduction and Sustained Clinical Benefits of CCM® Therapy at One Year.” Toronto Star, October 12, 2026. https://www.thestar.com/globenewswire/impulse-dynamics-presented-real-world-late-breaking-data-revealing-heart-failure-hospitalization-reduction-and-sustained/article_622f1936-fec0-5ee8-84ec-942ff4bcd12c.html.
Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.
Impulse Dynamics®, a global medical device company based in MARLTON, announced at the Heart Failure Society of America (HFSA) 2026 Annual Scientific Meeting on October 12, 2026 that their CCM® Therapy has shown significant benefits for patients with heart failure. The U.S. Post-Approval Study involved 530 participants across 71 sites, evaluating the long-term safety and clinical outcomes of CCM® Therapy as approved by the FDA. Results indicated reduced heart failure hospitalizations and improved patient quality of life, supporting the broader use of this therapy for heart failure patients.